Literature DB >> 23542068

Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study.

K Nadine Phoa1, Roos E Pouw1, Frederike G I van Vilsteren1, Carine M T Sondermeijer1, Fiebo J W Ten Kate2, Mike Visser2, Sybren L Meijer2, Mark I van Berge Henegouwen3, Bas L A M Weusten4, Erik J Schoon5, Rosalie C Mallant-Hent6, Jacques J G H M Bergman7.   

Abstract

BACKGROUND & AIMS: Radiofrequency ablation (RFA), with or without endoscopic resection effectively eradicates Barrett's esophagus (BE) containing high-grade intraepithelial neoplasia and/or early-stage cancer. We followed patients who received RFA for BE containing high-grade intraepithelial neoplasia and/or early-stage cancer for 5 years to determine the durability of treatment response.
METHODS: We followed 54 patients with BE (2-12 cm), previously enrolled in 4 consecutive cohort studies in which they underwent focal endoscopic resection in case of visible lesions (n = 40 [72%]), followed by serial RFA every 3 months. Patients underwent high-resolution endoscopy with narrow-band imaging at 6 and 12 months after treatment and then annually for 5 years (median, 61 months; interquartile range, 53-65 months); random biopsy samples were collected from neosquamous epithelium and gastric cardia. After 5 years, endoscopic ultrasound and endoscopic resection of neosquamous epithelium were performed. Outcomes included sustained complete remission of neoplasia or intestinal metaplasia (IM), IM in gastric cardia, or buried glands in neosquamous epithelium.
RESULTS: After 5 years, Kaplan-Meier analysis showed sustained complete remission of neoplasia and intestinal metaplasia in 90% of patients; neoplasia recurred in 3 patients and was managed endoscopically. Focal IM in the cardia was found in 19 of 54 patients (35%), in 53 of 1143 gastric cardia biopsies (4.6%). The incidence of IM of the cardia did not increase over time; and IM was diagnosed based on only a single biopsy in 89% of patients. Buried glands were detected in 3 of 3543 neosquamous epithelium biopsies (0.08%, from 3 patients). No endoscopic resection samples had buried glands.
CONCLUSIONS: Among patients who have undergone RFA with or without endoscopic resection for neoplastic BE, 90% remain in remission at 5-year follow-up, with all recurrences managed endoscopically. This treatment approach is therefore an effective and durable alternative to esophagectomy; www.trialregister.nl number, NTR2938.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23542068     DOI: 10.1053/j.gastro.2013.03.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  68 in total

1.  Measurement of the tumor invasion depth into the submucosa in early adenocarcinoma of the esophagus (pT1b): Can microns be the new standard for the endoscopist?

Authors:  Hendrik Manner; Oliver Pech
Journal:  United European Gastroenterol J       Date:  2015-12       Impact factor: 4.623

2.  Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma.

Authors:  Angelique Levert-Mignon; Michael J Bourke; Sarah J Lord; Andrew C Taylor; Antony R Wettstein; Melanie Edwards; Natalia K Botelho; Rebecca Sonson; Chatura Jayasekera; Oliver M Fisher; Melissa L Thomas; Finlay Macrae; Damian J Hussey; David I Watson; Reginald V Lord
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

3.  Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus.

Authors:  Kazuhiro Yasuda; Sung Eun Choi; Norman S Nishioka; David W Rattner; William P Puricelli; Angela C Tramontano; Seigo Kitano; Chin Hur
Journal:  Dig Dis Sci       Date:  2014-01-07       Impact factor: 3.199

4.  Update on the use of radiofrequency ablation for treatment of barrett esophagus.

Authors:  Gary W Falk
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-07

5.  Endoscopic management of high-grade dysplasia and intramucosal carcinoma: experience in a large academic medical center.

Authors:  Kyle A Perry; Jon P Walker; Mario Salazar; Andrew Suzo; Jeffrey W Hazey; W Scott Melvin
Journal:  Surg Endosc       Date:  2014-03       Impact factor: 4.584

6.  Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease.

Authors:  Dirk Schölvinck; Hannah Künzli; Sybren Meijer; Kees Seldenrijk; Mark van Berge Henegouwen; Jacques Bergman; Bas Weusten
Journal:  Surg Endosc       Date:  2016-06-29       Impact factor: 4.584

7.  Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus.

Authors:  Cary C Cotton; Rehan Haidry; Aaron P Thrift; Laurence Lovat; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2018-04-13       Impact factor: 22.682

8.  Durability and predictors of successful radiofrequency ablation for Barrett's esophagus.

Authors:  Sarina Pasricha; William J Bulsiewicz; Kelly E Hathorn; Srinadh Komanduri; V Raman Muthusamy; Richard I Rothstein; Herbert C Wolfsen; Charles J Lightdale; Bergein F Overholt; Daniel S Camara; Evan S Dellon; William D Lyday; Atilla Ertan; Gary W Chmielewski; Nicholas J Shaheen
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-09       Impact factor: 11.382

Review 9.  Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.

Authors:  Amrit K Kamboj; David A Katzka; Prasad G Iyer
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21

10.  Significance of Nissen fundoplication after endoscopic radiofrequency ablation of Barrett's esophagus.

Authors:  Ognjan Skrobić; Aleksandar Simić; Nebojša Radovanović; Nenad Ivanović; Marjan Micev; Predrag Peško
Journal:  Surg Endosc       Date:  2015-12-10       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.